CBO: Senate Compounding, Track-and-Trace Bill to Pack a Wallop for Industry; While S 959 Will Have Little Impact on the Federal Government

FDAnews Drug Daily Bulletin

July 19, 2013  | Vol. 10 No. 140

 

The private sector will bear the brunt of costs from combined Senate legislation on track-and-trace and compounding, according to a new federal cost estimate that casts doubt on an already precarious legislative effort. A Monday report from the Congressional Budget Office (CBO) estimates that S. 959, the Pharmaceutical Quality, Security and Accountability Act, will have little impact on the federal government.
Drug Industry Daily

CBO: Senate Compounding, Track-and-Trace Bill to Pack a Wallop for Industry

Drug Industry Daily

July 18, 2013  | Vol. 12 No. 139

 

The private sector will bear the brunt of costs from combined Senate legislation on track-and-trace and compounding, according to a new federal cost estimate that casts doubt on an already precarious legislativeeffort.

This article is viewable by subscribers only. To view this article, please select an option below.